Revelation Biosciences (REVB) CEO gets 532,829 RSUs in grant award filing

Q: What insider transaction did REVB CEO James Rolke report?

James Rolke, CEO and director of Revelation Biosciences, Inc. (REVB) , reported acquiring 532,829 shares of common stock on 01/08/2026 as an equity award.

Q: At what price were the new REVB shares awarded to the CEO?

The newly awarded 532,829 Revelation Biosciences common shares to CEO James Rolke were reported at a price of $0.90 per share .

Q: What type of equity did REVB grant to its CEO in this filing?

The award consists of Restricted Stock Units under the 2021 Equity Incentive Plan , which convert into Revelation Biosciences common stock as they vest.

Q: How do the REVB CEO’s Restricted Stock Units vest?

The filing states the Restricted Stock Units granted to CEO James Rolke vest quarterly over two years from the date of grant.

Q: Is this REVB Form 4 filing for a single reporting person?

Yes. The Form 4 indicates it is filed by one reporting person , James Rolke, who is both a director and the Chief Executive Officer of Revelation Biosciences.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Revelation Biosciences, Inc. insider filing shows its Chief Executive Officer and director, James Rolke, receiving a large equity grant. On 01/08/2026, he was awarded 532,829 shares of common stock at $0.90 per share, reported as an acquisition of non-derivative securities. These shares are described as Restricted Stock Units under the company’s 2021 Equity Incentive Plan, which vest quarterly over two years from the grant date.

Following this grant, Rolke is reported to beneficially own 933,489 shares of Revelation Biosciences common stock, held directly. The filing reflects routine equity compensation for a senior executive, with vesting tied to continued service over the two-year period.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Rolke James

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	532,829	$0.90	$480K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 933,489 shares (Direct)

Footnotes (1)

[object Object]

Form 4 Insider Transactions: What Each Field Means →

01/12/2026 - 05:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rolke James

(Last)

(First)

(Middle)

C/O REVELATION BIOSCIENCES, INC.

4660 LA JOLLA VILLAGE DR., SUITE 100

(Street)

SAN DIEGO

92122

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
REVELATION BIOSCIENCES, INC. [ REVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								400,660	D
Common Stock⁽¹⁾	01/08/2026		A		532,829	A	$0.9	933,489	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Restricted Stock Units under the 2021 Equity Incentive Plan. Vests quarterly over two years from the date of grant.

	/s/ J.P. Galda, as attorney-in-fact for James Rolke	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did REVB CEO James Rolke report?

James Rolke, CEO and director of Revelation Biosciences, Inc. (REVB), reported acquiring 532,829 shares of common stock on 01/08/2026 as an equity award.

At what price were the new REVB shares awarded to the CEO?

The newly awarded 532,829 Revelation Biosciences common shares to CEO James Rolke were reported at a price of $0.90 per share.

What type of equity did REVB grant to its CEO in this filing?

The award consists of Restricted Stock Units under the 2021 Equity Incentive Plan, which convert into Revelation Biosciences common stock as they vest.

How do the REVB CEO’s Restricted Stock Units vest?

The filing states the Restricted Stock Units granted to CEO James Rolke vest quarterly over two years from the date of grant.

How many REVB shares does the CEO own after this reported transaction?

After the reported equity grant, CEO James Rolke is shown as beneficially owning 933,489 shares of Revelation Biosciences common stock, held directly.

Is this REVB Form 4 filing for a single reporting person?

Yes. The Form 4 indicates it is filed by one reporting person, James Rolke, who is both a director and the Chief Executive Officer of Revelation Biosciences.